Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas.

Kaori OhnishiKentaro NakayamaMasako IshikawaTomoka IshibashiHitomi YamashitaKohei NakamuraToshiko MinamotoKouji IidaSultana RaziaNoriyoshi IshikawaSatoru Kyo

Published in: Archives of gynecology and obstetrics (2020)

These results suggest that MBT with V600E BRAF mutation may rarely progress to MOC, while MBT with G12D or G13D KRAS mutation may more commonly progress to MOC.

Keyphrases

low grade
high grade